secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001645113-24-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive
---------------------------------------------------------------------------

- Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.
- Net loss $33.4M ($0.31 per share); adjusted EBITDA $1.1M; cash and investments $951.2M.
- Phase 3 METIS trial in brain metastases from NSCLC met primary endpoint; presented at ASCO 2024.
- Active patients 3,963 as of June 30, 2024; prescriptions 1,634, up 5% YoY.
- Gross margin 77%; research & development expenses $55.0M; sales & marketing $56.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/0001645113-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/nvcr-20240725.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer